Empasiprubart Administration for Healthy Subjects

This trial tests a new treatment called empasiprubart to evaluate its effectiveness and safety. Participants will receive empasiprubart either through an autoinjector into the abdomen or thigh, or intravenously (directly into a vein). The study targets healthy adults weighing between 50 and 120 kg with no significant medical conditions. The trial consists of two parts, each using different methods of administering the treatment to compare effects. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the unique opportunity to be among the first to receive it.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that empasiprubart has been tested for safety in humans with positive results. Studies have found that when administered through an IV (a drip) or an autoinjector, participants undergo regular checks for side effects and vital signs. These studies found it to be generally safe, with no major safety issues reported.

For the IV version, research in patients with conditions like multifocal motor neuropathy showed it was well-tolerated and helped improve some symptoms. For the autoinjector version, the safety data also appeared favorable, with careful health checks revealing no major problems.

Empasiprubart is unique because it offers multiple ways to be administered, either intravenously (IV) or subcutaneously (SC) via an autoinjector (AI), giving patients and healthcare providers more flexibility. Unlike many standard treatments that might rely on one method of delivery, empasiprubart's options could potentially make it more convenient and accessible for different patient needs. Researchers are particularly excited about its innovative formulation, which could improve patient compliance and overall treatment experience.

This trial will evaluate different methods of administering empasiprubart to healthy subjects. Studies have shown that empasiprubart holds significant promise. In patients with multifocal motor neuropathy, a nerve disorder, an earlier study demonstrated that empasiprubart administered through an IV reduced the need for another treatment called IVIg by 91%, resulting in fewer treatments. Patients also reported stronger grip strength and an overall improvement in well-being. Additionally, other research has shown that empasiprubart reduces inflammation in conditions like dermatomyositis, a muscle disease. These findings suggest that empasiprubart could be effective for various conditions.²⁴⁶⁷⁸